Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : to Buy KaNDy Therapeutics

share with twitter share with LinkedIn share with facebook
08/11/2020 | 03:12am EDT

By Olivia Bugault

Bayer AG will acquire U.K.-based biotech company KaNDy Therapeutics Ltd. in order to expand its women's health-care pipeline with a potential new medicine, both companies said Tuesday.

"KaNDy Therapeutics recently completed the Phase IIb with NT-814, a first in class, non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist, publishing positive data for the treatment of frequent symptoms of the menopause, hot flashes and night sweats," it said.

The phase 3 clinical trial should start in 2021 and, once the medicine is approved, it could generate peak sales potential of more than 1 billion euros ($1.17 billion) globally, they said.

Under the deal, the German pharmaceutical and chemical conglomerate will pay an upfront consideration of $425 million and a potential additional consideration in the form of milestone payments, the companies said.

The deal includes "potential milestone payments of up to $450 million until launch followed by potential additional triple-digit million sales milestone payments," they said.

The deal is expected to close by September 2020, once approved by antitrust authorities in particular, they said.

 

Write to Olivia Bugault at olivia.bugault@wsj.com

 

share with twitter share with LinkedIn share with facebook
All news about BAYER AG
09/24BAYER : resolves more Roundup cases, judge keeps pause on litigation
RE
09/24BAYER : resolves more Roundup cases, judge keeps pause on litigation
RE
09/21BAYER : opens application window for Grants4Ag
PU
09/18GLOBAL MARKETS LIVE : Tiktok, CaixaBank, Moderna…
09/18Covestro denies it is in takeover talks with Apollo
RE
09/17EXCLUSIVE : In the weeds - How Bayer, U.S. government teamed up against Thailand..
RE
09/17IN THE WEEDS : How Bayer, U.S. govt teamed up against Thailand's glyphosate ban
RE
09/17BAYER : New data reinforce strong clinical profile of Vitrakvi™ for patien..
PU
09/15BAYER : settles thousands of U.S. Roundup cases with trial attorneys
RE
09/15Bayer settles thousands of U.S. Roundup cases with trial attorneys
RE
More news
Financials
Sales 2020 43 305 M 50 377 M 50 377 M
Net income 2020 -2 690 M -3 129 M -3 129 M
Net Debt 2020 32 651 M 37 983 M 37 983 M
P/E ratio 2020 -15,9x
Yield 2020 5,31%
Capitalization 52 530 M 61 032 M 61 108 M
EV / Sales 2020 1,97x
EV / Sales 2021 1,89x
Nbr of Employees 101 168
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,72 €
Last Close Price 53,47 €
Spread / Highest target 106%
Spread / Average Target 47,2%
Spread / Lowest Target -14,0%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-26.56%61 032
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402